The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Biora Inc. | COM NEW | 74319F305 | 23,717,584 | 10,929,762 | SH | SOLE | 10,929,762 | 0 | 0 | ||
Biora Inc. | Note 7.250% 12/0 | 74319FAB3 | 27,960,943 | 53,500,000 | PRN | SOLE | 0 | 0 | 53,500,000 | ||
RVL PHARMACEUTICALS PLC | SHS | G6S41R101 | 1,264,399 | 14,600,444 | SH | SOLE | 14,600,444 | 0 | 0 | ||
Omeros Corp | NOTE 6.250%11/1 | 682143AE2 | 11,255,556 | 11,005,000 | PRN | SOLE | 0 | 0 | 11,005,000 | ||
Omeros Corp | NOTE 5.250% 2/1 | 682143AG7 | 44,643,626 | 72,979,000 | PRN | SOLE | 0 | 0 | 72,979,000 | ||
PUMA BIOTECHNOLOGY INC | COM | 74587V107 | 4,713,260 | 1,792,114 | SH | SOLE | 1,792,114 | 0 | 0 |